Blueprint Medicines Corporation   Report issue

Founded: Cambridge MA United States (2011)

Organization Overview

First Clinical Trial
2015
NCT02508467
First Marketed Drug
2020
avapritinib (Ayvakit)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

BLUEPRINT MEDICINES | Blueprint Medicines Corporation